STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $321,977 | -84.5% | 81,720 | -58.2% | 0.00% | – |
Q2 2023 | $2,076,017 | +4.7% | 195,298 | -17.9% | 0.00% | – |
Q1 2023 | $1,982,249 | -34.7% | 237,965 | -27.7% | 0.00% | -100.0% |
Q4 2022 | $3,037,649 | -12.9% | 329,106 | +21.1% | 0.00% | 0.0% |
Q3 2022 | $3,489,000 | +110.9% | 271,781 | +117.0% | 0.00% | – |
Q2 2022 | $1,654,000 | -38.9% | 125,237 | -2.6% | 0.00% | -100.0% |
Q1 2022 | $2,706,000 | +1239.6% | 128,532 | +1426.1% | 0.00% | – |
Q4 2021 | $202,000 | -81.3% | 8,422 | -80.2% | 0.00% | – |
Q3 2021 | $1,083,000 | -63.1% | 42,567 | -51.2% | 0.00% | – |
Q2 2021 | $2,936,000 | +68.5% | 87,232 | +94.6% | 0.00% | – |
Q1 2021 | $1,742,000 | +45.0% | 44,830 | +131.1% | 0.00% | – |
Q4 2020 | $1,201,000 | +149.2% | 19,400 | +34.7% | 0.00% | – |
Q3 2020 | $482,000 | +11.6% | 14,400 | -23.7% | 0.00% | – |
Q1 2020 | $432,000 | +45.9% | 18,865 | +80.3% | 0.00% | – |
Q4 2019 | $296,000 | -89.8% | 10,465 | -89.5% | 0.00% | -100.0% |
Q2 2019 | $2,911,000 | – | 99,818 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 17,161,713 | $1,062,825,000 | 82.06% |
RTW INVESTMENTS, LP | 3,544,248 | $219,495,000 | 3.68% |
Cormorant Asset Management, LP | 1,437,807 | $89,043,000 | 2.12% |
Redmile Group, LLC | 2,686,234 | $166,358,000 | 2.01% |
ACUTA CAPITAL PARTNERS, LLC | 92,500 | $5,729,000 | 1.56% |
Pinz Capital Management, LP | 34,200 | $2,118,000 | 0.96% |
Birchview Capital, LP | 20,000 | $1,239,000 | 0.71% |
HighVista Strategies LLC | 17,668 | $1,094,000 | 0.70% |
GILDER GAGNON HOWE & CO LLC | 1,470,841 | $91,089,000 | 0.45% |
Perceptive Advisors | 671,978 | $41,616,000 | 0.45% |